In Haicheng's top conference room, the final negotiations for Hengsheng Group's acquisition of "Xinke Pharmaceutical" reached a deadlock. Li Mochenfang's legal team has prepared all the documents and is just waiting for the other party to sign. The door was pushed open, and Shen Qingci, as the newly replaced chief attorney, entered alone with an old briefcase.
Instead of looking at the pile of acquisition documents, she went straight to the projector and inserted the USB flash drive: "Mr. Li, before discussing the price, please take a look at this scanned copy of the environmental fine for your subsidiary 'Kangyuan Biotech' three years ago - according to the "Administrative Measures for Major Asset Restructuring of Listed Companies", undisclosed major administrative penalties may lead to the rejection of the entire acquisition."
